192 related articles for article (PubMed ID: 30380358)
1. Health related quality of life for multiple myeloma patients according to treatment strategy after autologous stem cell transplant: a cross-sectional study using EORTC, EQ-5D and MY-20 scales.
Tay J; Vij R; Norkin M; Buadi F; Kindwall-Keller TL; Roberts JS; White DJ; Wood RP; Blanthorn-Hazell SE; Rossi AC; Dhanasiri S; Zafar F; Newhouse K; McCurdy AR
Leuk Lymphoma; 2019 May; 60(5):1275-1282. PubMed ID: 30380358
[TBL] [Abstract][Full Text] [Related]
2. Mapping EORTC QLQ-C30 and QLQ-MY20 to EQ-5D in patients with multiple myeloma.
Proskorovsky I; Lewis P; Williams CD; Jordan K; Kyriakou C; Ishak J; Davies FE
Health Qual Life Outcomes; 2014 Mar; 12():35. PubMed ID: 24618388
[TBL] [Abstract][Full Text] [Related]
3. Health-related quality of life in transplant eligible multiple myeloma patients with or without early ASCT in the real-world setting.
Asrar MM; Lad DP; Bansal D; Prinja S; Khadwal A; Prakash G; Jain A; Jandial A; Malhotra P
Leuk Lymphoma; 2021 Dec; 62(13):3271-3277. PubMed ID: 34269156
[TBL] [Abstract][Full Text] [Related]
4. Quality of life is maintained with ixazomib maintenance in post-transplant newly diagnosed multiple myeloma: The TOURMALINE-MM3 trial.
Schjesvold F; Goldschmidt H; Maisnar V; Spicka I; Abildgaard N; Rowlings P; Cain L; Romanus D; Suryanarayan K; Rajkumar V; Odom D; Gnanasakthy A; Dimopoulos M
Eur J Haematol; 2020 May; 104(5):443-458. PubMed ID: 31880006
[TBL] [Abstract][Full Text] [Related]
5. Health-related quality of life of patients with multiple myeloma: A real-world study in China.
Li X; Liu J; Chen M; Gu J; Huang B; Zheng D; Li J
Cancer Med; 2020 Nov; 9(21):7896-7913. PubMed ID: 32881377
[TBL] [Abstract][Full Text] [Related]
6. Quality of life during and following sequential treatment of previously untreated patients with multiple myeloma: findings of the Medical Research Council Myeloma IX randomised study.
Royle KL; Gregory WM; Cairns DA; Bell SE; Cook G; Owen RG; Drayson MT; Davies FE; Jackson GH; Morgan GJ; Child JA
Br J Haematol; 2018 Sep; 182(6):816-829. PubMed ID: 29984830
[TBL] [Abstract][Full Text] [Related]
7. Health-related quality of life and quality-adjusted progression free survival for carfilzomib and dexamethasone maintenance following salvage autologous stem-cell transplantation in patients with multiple myeloma: a randomized phase 2 trial by the Nordic Myeloma Study Group.
Nielsen LK; Schjesvold F; Möller S; Guldbrandsen N; Hansson M; Remes K; Peceliunas V; Abildgaard N; Gregersen H; King MT
J Patient Rep Outcomes; 2024 Feb; 8(1):15. PubMed ID: 38315268
[TBL] [Abstract][Full Text] [Related]
8. Assessment of the psychometric properties of the Spanish version of EORTC QLQ-MY20 and evaluation of health-related quality of Life outcomes in patients with relapsed and/or refractory multiple myeloma in the real-world setting in Spain: results from the CharisMMa study.
Dachs LR; Gaisán CM; Bustamante G; López SG; García EG; Persona EP; González-Calle V; Auzmendi MS; Pérez JMA; González Montes Y; Ríos Tamayo R; de Miguel Llorente D; Bernal LP; Mayol AS; Caro CC; Grande M; Fernández-Nistal A; Naves A; Miguel EMOS
Leuk Lymphoma; 2023; 64(11):1847-1856. PubMed ID: 37539698
[TBL] [Abstract][Full Text] [Related]
9. Impact of the treatment-free interval on health-related quality of life in patients with multiple myeloma: a UK cross-sectional survey.
Acaster S; Gaugris S; Velikova G; Yong K; Lloyd AJ
Support Care Cancer; 2013 Feb; 21(2):599-607. PubMed ID: 22886429
[TBL] [Abstract][Full Text] [Related]
10. Patient-Reported Outcome Results From the Open-Label, Randomized Phase III Myeloma X Trial Evaluating Salvage Autologous Stem-Cell Transplantation in Relapsed Multiple Myeloma.
Ahmedzai SH; Snowden JA; Ashcroft AJ; Cairns DA; Williams C; Hockaday A; Cavenagh JD; Ademokun D; Tholouli E; Allotey D; Dhanapal V; Jenner M; Yong K; Cavet J; Hunter H; Bird JM; Pratt G; Parrish C; Brown JM; Morris TCM; Cook G;
J Clin Oncol; 2019 Jul; 37(19):1617-1628. PubMed ID: 30969846
[TBL] [Abstract][Full Text] [Related]
11. Exercise prehabilitation for people with myeloma undergoing autologous stem cell transplantation: results from PERCEPT pilot randomised controlled trial.
McCourt O; Fisher A; Ramdharry G; Land J; Roberts AL; Rabin N; Yong K
Acta Oncol; 2023 Jul; 62(7):696-705. PubMed ID: 36794394
[TBL] [Abstract][Full Text] [Related]
12. Self-Reported Quality of Life and Symptom Burden in Ambulatory Patients With Multiple Myeloma on Disease-Modifying Treatment.
Kiely F; Cran A; Finnerty D; O'Brien T
Am J Hosp Palliat Care; 2017 Aug; 34(7):671-676. PubMed ID: 27141015
[TBL] [Abstract][Full Text] [Related]
13. Bayesian statistical models to estimate EQ-5D utility scores from EORTC QLQ data in myeloma.
Kharroubi SA; Edlin R; Meads D; McCabe C
Pharm Stat; 2018 Jul; 17(4):358-371. PubMed ID: 29460413
[TBL] [Abstract][Full Text] [Related]
14. Health-related quality of life in multiple myeloma survivors treated with high dose chemotherapy followed by autologous peripheral blood progenitor cell transplantation: a retrospective analysis.
Slovacek L; Slovackova B; Pavlik V; Hrstka Z; Macingova Z; Jebavy L; Horacek JM
Neoplasma; 2008; 55(4):350-5. PubMed ID: 18505348
[TBL] [Abstract][Full Text] [Related]
15. Impact of post-transplantation maintenance therapy on health-related quality of life in patients with multiple myeloma: data from the Connect® MM Registry.
Abonour R; Wagner L; Durie BGM; Jagannath S; Narang M; Terebelo HR; Gasparetto CJ; Toomey K; Hardin JW; Kitali A; Gibson CJ; Srinivasan S; Swern AS; Rifkin RM
Ann Hematol; 2018 Dec; 97(12):2425-2436. PubMed ID: 30056582
[TBL] [Abstract][Full Text] [Related]
16. Real-World Evaluation of Health-Related Quality of Life in Patients With Multiple Myeloma From Germany.
Engelhardt M; Ihorst G; Singh M; Rieth A; Saba G; Pellan M; Lebioda A
Clin Lymphoma Myeloma Leuk; 2021 Feb; 21(2):e160-e175. PubMed ID: 33218965
[TBL] [Abstract][Full Text] [Related]
17. Quality of life and rehabilitation in social and professional life after autologous stem cell transplantation.
Hensel M; Egerer G; Schneeweiss A; Goldschmidt H; Ho AD
Ann Oncol; 2002 Feb; 13(2):209-17. PubMed ID: 11885996
[TBL] [Abstract][Full Text] [Related]
18. The influence of baseline characteristics and disease stage on health-related quality of life in multiple myeloma: findings from six randomized controlled trials.
Robinson D; Esseltine DL; Regnault A; Meunier J; Liu K; van de Velde H
Br J Haematol; 2016 Aug; 174(3):368-81. PubMed ID: 27265837
[TBL] [Abstract][Full Text] [Related]
19. Use of the European Organisation for Research and Treatment of Cancer multiple myeloma module (EORTC QLQ-MY20): a review of the literature 25 years after development.
Forde K; Cocks K; Wells JR; McMillan I; Kyriakou C;
Blood Cancer J; 2023 May; 13(1):79. PubMed ID: 37193682
[TBL] [Abstract][Full Text] [Related]
20. Autologous stem cell transplantation in multiple myeloma is not dead but alive and well.
Martino M; Morabito F
Expert Opin Biol Ther; 2015 Feb; 15(2):149-54. PubMed ID: 25435056
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
